vs
Side-by-side financial comparison of Dayforce (DAY) and Bio-Techne (TECH). Click either name above to swap in a different company.
Dayforce is the larger business by last-quarter revenue ($481.6M vs $295.9M, roughly 1.6× Bio-Techne). Bio-Techne runs the higher net margin — 12.8% vs -40.9%, a 53.7% gap on every dollar of revenue. On growth, Dayforce posted the faster year-over-year revenue change (9.5% vs -6.4%). Over the past eight quarters, Dayforce's revenue compounded faster (9.8% CAGR vs 4.2%).
Dayforce, Inc., formerly Ceridian, is an American human resources software and services company.
Bio-Techne Corporation is an American life sciences company that develops, manufactures and sells life science reagents, instruments and services for the research, diagnostic, and bioprocessing markets.
DAY vs TECH — Head-to-Head
Income Statement — Q3 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $481.6M | $295.9M |
| Net Profit | $-196.8M | $38.0M |
| Gross Margin | — | 64.6% |
| Operating Margin | 6.3% | 18.4% |
| Net Margin | -40.9% | 12.8% |
| Revenue YoY | 9.5% | -6.4% |
| Net Profit YoY | -9940.0% | 68.3% |
| EPS (diluted) | $-1.23 | $0.24 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $295.9M | ||
| Q3 25 | $481.6M | — | ||
| Q2 25 | $464.7M | $317.0M | ||
| Q1 25 | $481.8M | $316.2M | ||
| Q4 24 | $465.2M | $297.0M | ||
| Q3 24 | $440.0M | $289.5M | ||
| Q2 24 | $423.3M | $306.1M | ||
| Q1 24 | $431.5M | $303.4M |
| Q4 25 | — | $38.0M | ||
| Q3 25 | $-196.8M | — | ||
| Q2 25 | $21.3M | $-17.7M | ||
| Q1 25 | $14.9M | $22.6M | ||
| Q4 24 | $10.8M | $34.9M | ||
| Q3 24 | $2.0M | $33.6M | ||
| Q2 24 | $-1.8M | $40.6M | ||
| Q1 24 | $7.1M | $49.1M |
| Q4 25 | — | 64.6% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 62.7% | ||
| Q1 25 | — | 67.9% | ||
| Q4 24 | 47.0% | 65.3% | ||
| Q3 24 | 45.8% | 63.2% | ||
| Q2 24 | 44.1% | 66.4% | ||
| Q1 24 | 47.6% | 67.4% |
| Q4 25 | — | 18.4% | ||
| Q3 25 | 6.3% | — | ||
| Q2 25 | 9.1% | -7.5% | ||
| Q1 25 | 6.4% | 12.2% | ||
| Q4 24 | 6.1% | 16.0% | ||
| Q3 24 | 4.7% | 13.8% | ||
| Q2 24 | 3.3% | 15.0% | ||
| Q1 24 | 9.4% | 22.1% |
| Q4 25 | — | 12.8% | ||
| Q3 25 | -40.9% | — | ||
| Q2 25 | 4.6% | -5.6% | ||
| Q1 25 | 3.1% | 7.1% | ||
| Q4 24 | 2.3% | 11.7% | ||
| Q3 24 | 0.5% | 11.6% | ||
| Q2 24 | -0.4% | 13.3% | ||
| Q1 24 | 1.6% | 16.2% |
| Q4 25 | — | $0.24 | ||
| Q3 25 | $-1.23 | — | ||
| Q2 25 | $0.13 | $-0.11 | ||
| Q1 25 | $0.09 | $0.14 | ||
| Q4 24 | $0.07 | $0.22 | ||
| Q3 24 | $0.01 | $0.21 | ||
| Q2 24 | $-0.01 | $0.26 | ||
| Q1 24 | $0.04 | $0.31 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $627.6M | $172.9M |
| Total DebtLower is stronger | $631.1M | $260.0M |
| Stockholders' EquityBook value | $2.7B | $2.0B |
| Total Assets | $8.7B | $2.5B |
| Debt / EquityLower = less leverage | 0.23× | 0.13× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $172.9M | ||
| Q3 25 | $627.6M | — | ||
| Q2 25 | $625.2M | $162.2M | ||
| Q1 25 | $557.3M | $140.7M | ||
| Q4 24 | $579.7M | $177.5M | ||
| Q3 24 | $494.1M | $187.5M | ||
| Q2 24 | $465.4M | $152.9M | ||
| Q1 24 | $392.5M | $145.3M |
| Q4 25 | — | $260.0M | ||
| Q3 25 | $631.1M | — | ||
| Q2 25 | $631.8M | $346.0M | ||
| Q1 25 | $632.4M | $330.0M | ||
| Q4 24 | $1.2B | $300.0M | ||
| Q3 24 | $1.2B | $300.0M | ||
| Q2 24 | $1.2B | $319.0M | ||
| Q1 24 | $1.2B | $389.0M |
| Q4 25 | — | $2.0B | ||
| Q3 25 | $2.7B | — | ||
| Q2 25 | $2.7B | $1.9B | ||
| Q1 25 | $2.6B | $2.0B | ||
| Q4 24 | $2.5B | $2.1B | ||
| Q3 24 | $2.6B | $2.1B | ||
| Q2 24 | $2.5B | $2.1B | ||
| Q1 24 | $2.4B | $2.0B |
| Q4 25 | — | $2.5B | ||
| Q3 25 | $8.7B | — | ||
| Q2 25 | $8.5B | $2.6B | ||
| Q1 25 | $9.5B | $2.6B | ||
| Q4 24 | $9.1B | $2.7B | ||
| Q3 24 | $8.1B | $2.7B | ||
| Q2 24 | $9.0B | $2.7B | ||
| Q1 24 | $10.8B | $2.7B |
| Q4 25 | — | 0.13× | ||
| Q3 25 | 0.23× | — | ||
| Q2 25 | 0.23× | 0.18× | ||
| Q1 25 | 0.24× | 0.16× | ||
| Q4 24 | 0.47× | 0.14× | ||
| Q3 24 | 0.47× | 0.14× | ||
| Q2 24 | 0.49× | 0.15× | ||
| Q1 24 | 0.50× | 0.19× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $31.2M | — |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | — | ||
| Q3 25 | $31.2M | — | ||
| Q2 25 | $112.7M | $98.2M | ||
| Q1 25 | $49.6M | $41.1M | ||
| Q4 24 | $81.0M | $84.3M | ||
| Q3 24 | $91.8M | $63.9M | ||
| Q2 24 | $99.2M | $75.5M | ||
| Q1 24 | $9.1M | $81.0M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $93.3M | ||
| Q1 25 | — | $31.0M | ||
| Q4 24 | — | $77.5M | ||
| Q3 24 | — | $54.7M | ||
| Q2 24 | — | $57.5M | ||
| Q1 24 | — | $64.5M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 29.4% | ||
| Q1 25 | — | 9.8% | ||
| Q4 24 | — | 26.1% | ||
| Q3 24 | — | 18.9% | ||
| Q2 24 | — | 18.8% | ||
| Q1 24 | — | 21.3% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 1.5% | ||
| Q1 25 | — | 3.2% | ||
| Q4 24 | — | 2.3% | ||
| Q3 24 | — | 3.2% | ||
| Q2 24 | — | 5.9% | ||
| Q1 24 | — | 5.4% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 5.29× | — | ||
| Q1 25 | 3.33× | 1.82× | ||
| Q4 24 | 7.50× | 2.42× | ||
| Q3 24 | 45.90× | 1.90× | ||
| Q2 24 | — | 1.86× | ||
| Q1 24 | 1.28× | 1.65× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DAY
| Dayforce Recurring | $333.0M | 69% |
| Cloud And Bureau Professional Services And Other | $78.5M | 16% |
| Float | $42.2M | 9% |
| Powerpay Recurring | $19.7M | 4% |
| Other Recurring | $8.2M | 2% |
TECH
| Diagnostics And Spatial Biology | $81.2M | 27% |
| EMEA Excluding UK | $75.4M | 25% |
| Other | $42.4M | 14% |
| Instruments | $29.6M | 10% |
| APAC Excluding Greater China | $22.7M | 8% |
| Services | $22.3M | 8% |
| GB | $13.7M | 5% |
| Royalty | $8.5M | 3% |
